secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2022-09-01T23:59:59+00:00
Accession:  0001558370-22-014127
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix BioTherapeutics enters fill/finish deal with Chiesi for PRX-102 launch
-------------------------------------------------------------------------------

- Agreement with Chiesi for commercial fill/finish services for PRX-102 (Fabry disease candidate).
- Protalix to supply drug substance; Chiesi will provide fill/finish services for global launch.
- Term through Dec 31, 2025, renewable for 7 years by mutual agreement.
- Letter Agreement modifies License Agreements to establish Chiesi as supplier and potential alternate source.
- Agreement supports anticipated launch; no financial terms disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837022014127/0001558370-22-014127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837022014127/plx-20220829x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-014127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer